ARS Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
SPRY$3.15+12.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and par value data)
| June 30, 2024 | December 31, 2023 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $36,626 | $70,971 |
| Short-term investments | 182,118 | 157,389 |
| Prepaid expenses and other current assets | 1,994 | 3,366 |
| Total current assets | 220,738 | 231,726 |
| Right-of-use asset | 146 | 250 |
| Fixed assets, net | 636 | 574 |
| Other assets | 446 | 638 |
| Total assets | $221,966 | $233,188 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities (including related party amounts of $122 and $178, respectively) | $6,565 | $2,154 |
| Lease liability, current | 160 | 237 |
| Total current liabilities | 6,725 | 2,391 |
| Lease liability, net of current portion | — | 37 |
| Total liabilities | 6,725 | 2,428 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value per share; 200,000,000 shares authorized at June 30, 2024 and December 31, 2023; 96,939,797 and 96,414,963 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | 10 | 10 |
| Additional paid-in capital | 369,487 | 362,004 |
| Accumulated other comprehensive (loss) gain, net | (145) | 49 |
| Accumulated deficit | (154,111) | (131,303) |
| Total stockholders’ equity | 215,241 | 230,760 |
| Total liabilities and stockholders’ equity | $221,966 | $233,188 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.